VRTX
Vertex Pharmaceuticals margins
- Stocks
- Healthcare
- NASDAQ: VRTX
- Margins
The Vertex Pharmaceuticals reports a gross margin of 86%, an operating margin of 37.9%, an EBITDA margin of 43.7%, and a net margin of 35%. Among the available margins, EBITDA margin improved the most and gross margin declined the most, by 3.6 and 0.1 percentage points respectively.
VRTX margin history
Over the last 3 years, Vertex Pharmaceuticals's margins averaged 86.44% gross, 23.59% operating, 30.33% EBITDA, and 21.31% net. For Vertex Pharmaceuticals, operating, EBITDA, and net margins are above their three-year averages, while gross margin is below its three-year average.
VRTX margin expansion
From the same period last year, operating margin expanded by 3.5 percentage points, EBITDA margin by 3.6 percentage points, and net margin by 3.1 percentage points, while gross margin contracted by 0.1 percentage points.
VRTX Gross margin
Over the last 3 years, Vertex Pharmaceuticals's gross margin averaged 86.44%. Currently, Vertex Pharmaceuticals's current gross margin is 86%, which is 0.4 percentage points below its three-year average. During this period, gross margin reached a high of 87.8% in Sep 2023 and a low of 86% in Mar 2025.
VRTX Operating margin
Over the last 3 years, the average operating margin for Vertex Pharmaceuticals was 23.59%. The current operating margin stands at 37.9%, 14.3 percentage points above its three-year average. Vertex Pharmaceuticals's operating margin ranged from a low of -6.7% in Mar 2025 to a high of 40.7% in Mar 2024.
VRTX EBITDA margin
In the last 3 years, Vertex Pharmaceuticals had an average EBITDA margin of 30.33%. At present, Vertex Pharmaceuticals's current EBITDA margin is 43.7%, which is 13.4 percentage points above its three-year average. Looking back over the last 3 years, Vertex Pharmaceuticals's EBITDA margin reached 49.2% at its highest point in Mar 2024 and -0.7% at its lowest in Mar 2025.
VRTX Net margin
Vertex Pharmaceuticals recorded an average net margin of 21.31% across the last 3 years. The current net margin of 35% is 13.7 percentage points above its three-year average. Vertex Pharmaceuticals's net margin ranged from a low of -8.9% in Mar 2025 to a high of 39.5% in Mar 2024.
VRTX margin group comparison
Vertex Pharmaceuticals's gross margin of 86% is higher than the Healthcare sector and its peers average but lower than the industry average. In comparison with the Healthcare sector average of 68.5%, Vertex Pharmaceuticals's gross margin is 26% higher.
VRTX margin peer comparison
Frequently asked questions
What is Vertex Pharmaceuticals's gross margin?
The current gross margin for VRTX is 86% as of Jun 30, 2026.
What is Vertex Pharmaceuticals's operating margin?
For the period ending Jun 30, 2026, VRTX recorded an operating margin of 37.9%.
What is Vertex Pharmaceuticals's EBITDA margin?
The current EBITDA margin for VRTX is 43.7% as of Jun 30, 2026.
What is Vertex Pharmaceuticals's net margin?
For the period ending Jun 30, 2026, VRTX recorded a net margin of 35%.
What are the average margins of VRTX?
The three-year average margins for VRTX were 86.4% gross, 23.6% operating, 30.3% EBITDA, and 21.3% net.
What are the highest historical margins of VRTX?
Over the last 5 years, Vertex Pharmaceuticals's highest margins were 88.1% gross in Jun 2022, 48.2% operating in Jun 2022, 49.7% EBITDA in Dec 2022, and 39.5% net in Mar 2024.
What are the lowest historical margins of VRTX?
Within the 5-year period, VRTX recorded its lowest margins at 86% gross in Mar 2025, -6.7% operating in Mar 2025, -0.7% EBITDA in Mar 2025, and -8.9% net in Mar 2025.